Atrial fibrillation, the most common sustained cardiac arrhythmia, becomes increasingly prevalent with age, and contemporary patients are typically older, frailer and burdened by multiple chronic conditions. This complexity raises the risk not only of stroke and bleeding but also of non-cardiovascular events and hospital admissions, driving substantial healthcare costs. The ABC pathway was proposed as a structured framework to streamline integrated management: ‘A’ for anticoagulation and stroke risk avoidance, ‘B’ for better symptom control, and ‘C’ for cardiovascular and comorbidity optimisation. Observational studies repeatedly linked adherence to the pathway with lower mortality, stroke and bleeding, and two cluster-randomised trials in Asia—one app-based in largely urban China and one delivered by village doctors with telehealth support in rural settings—had shown that ABC implementation improved guideline adherence and reduced adverse outcomes, including hospitalisations.

What remained unknown was whether the same approach would work in European healthcare systems, specifically among patients aged 65 or older with atrial fibrillation and at least one additional chronic condition. The AFFIRMO investigators, led by Gregory Y.H. Lip and Marco Proietti, designed a multicentre, open-label cluster-randomised trial across Bulgaria, Denmark, Italy, Romania, Serbia and Spain. Clinical centres, not individual patients, were randomised to deliver either the integrated mHealth intervention—dubbed the iABC system—or routine guideline-based care. The intervention combined a patient-facing mobile application with a clinician dashboard, and every intervention patient underwent a comprehensive geriatric assessment at baseline to identify functional domains requiring management.

The AFFIRMO Mobile App collected daily data on vital signs, oral anticoagulant adherence, arrhythmia symptoms and chronic conditions, while dispensing tailored health tips for lifestyle and comorbidity management. Each patient also completed the Patient Health Engagement scale at activation, which determined the level of personalised educational material they received about atrial fibrillation. On the clinical side, the AFFIRMO Clinician Dashboard summarised app usage and patient-entered data, organised by the three ABC pillars, to inform follow-up consultations. Between April 2024 and January 2025, the trial enrolled 1,260 patients, with 634 assigned to the iABC system and 626 to usual care. Follow-up visits occurred at 3, 6 and 12 months, and the primary endpoint was unplanned all-cause hospitalisation during one year of follow-up, adjudicated by a blinded event validation committee.

The enrolled population reflected the modern reality of atrial fibrillation care: a mean age of 73 to 74 years, a median CHA2DS2-VASc stroke risk score of 4, and a heavy burden of comorbidity. Roughly 40 percent had more than two chronic conditions, hypertension treated with multiple drugs was nearly universal, and polypharmacy affected 72 percent of participants. Yet the trial’s most consequential baseline finding was how well these patients were already being treated: 97.3 percent were on oral anticoagulation, overwhelmingly direct oral anticoagulants, and use of beta-blockers, anti-arrhythmic drugs and other guideline-directed therapies was uniformly high. Comprehensive geriatric assessment in the intervention arm revealed a largely functionally preserved cohort, with 95.7 percent showing normal cognition, 83.9 percent normal nutritional status, and only about 20 percent reporting meaningful mobility impairment.

After a mean follow-up of 367 days, unplanned all-cause hospitalisation occurred in 17.1 percent of the iABC group versus 18.2 percent of the usual care group—an adjusted odds ratio of 0.95 with a 95 percent confidence interval of 0.61 to 1.49 and a p-value of 0.84. Sensitivity analyses, including a Cox proportional hazards model and a composite endpoint of hospitalisation or death, told the same neutral story. No secondary endpoint differed between groups: all-cause death, any hospitalisation, stroke or cardiovascular death, heart failure events, renal worsening, and major bleeding, which occurred in only 0.7 percent of all participants, were statistically indistinguishable across arms. Subgroup analyses by age, sex, comorbidity count, medication number and country revealed no hidden pockets of benefit.

The investigators attribute the null result to a convergence of factors, each instructive in its own right. First, the trial’s power calculation assumed a 30 percent event rate in usual care and a 25 percent relative reduction with the intervention; instead, usual care produced only an 18.2 percent hospitalisation rate. With such low residual risk, several thousand patients would have been required to detect a statistically significant difference. Second, the baseline quality of care starkly contrasts with the prior Asian trials: in the mAFA trial, oral anticoagulant use at baseline was just 48.4 percent in usual care, and in the MIRACLE-AF rural trial it was around 11 percent. In those settings, the ABC intervention raised anticoagulation dramatically and reduced hospitalisations. In AFFIRMO, with anticoagulation already at 97 percent, there was simply little therapeutic ground left for a digital nudge to reclaim.

Third, and perhaps most telling, patients barely used the app. The median percentage of days on which patients accessed the AFFIRMO Mobile App was 15.1 percent, and 68.5 percent of patients fell into the lowest tertile of use, opening the app on only about one-third or fewer of their study days. The authors point to well-documented implementation barriers—digital literacy in an older population, workflow incompatibility, and difficulty integrating digital tools into complex health systems. Clinical decision support, they note, only works when it is actually used; in the O’CAFÉ trial, modest overall effects sharpened into significant anticoagulation improvements only among clinicians who actively engaged with the tool. Because the mobile app is half of the iABC system, its companion physician dashboard inheriting the consequences of underuse, suboptimal engagement directly undermined the intervention’s theoretical effectiveness.

Fourth, comprehensive geriatric assessment itself ran into a ceiling effect. Although more than half of the intervention patients showed some degree of frailty on the FRAIL scale, most were robust on objective measures of daily functioning, cognition, nutrition and mood. In such high-functioning individuals, geriatric assessment may serve a descriptive rather than an interventional role, and prior evidence suggests little clinical benefit from CGA in robust patients. The trial’s design assumed more functional impairment than it found, constraining the scope for assessment-driven management changes. Not all signals were negative, however: patients in the intervention arm showed numerically higher uptake of several guideline-directed treatments at the final visit, including mineralocorticoid receptor antagonists, SGLT2 inhibitors and anti-arrhythmic drugs, and a significantly lower rate of uncontrolled systolic blood pressure at 12 months (1.5 versus 4.0 percent), hinting at secondary improvements in care quality even without hard outcome benefits.

The broader lesson echoes the recent STEEER-AF trial, in which an electronic education programme for clinicians also yielded only marginal improvements because guideline adherence was already high in both arms. The authors emphasise that the results do not disqualify integrated care or the ABC pathway, which remains embedded in European Society of Cardiology guidance through the 2020 ABC framework and the 2024 AF-CARE scheme. Rather, they argue, integrated care interventions and digital health tools must be targeted at settings with genuine unmet clinical need—populations with low baseline guideline adherence, higher residual risk, or greater functional impairment. Future studies may also need easier-to-use apps, co-designed with older patients, and more selected populations in which the theoretical benefit of holistic optimisation has room to translate into fewer hospitalisations. For now, AFFIRMO stands as a rigorous, well-conducted demonstration that in medicine, as in engineering, the marginal return on optimisation shrinks as the system approaches its ceiling—and that digital tools, however elegantly engineered, cannot multiply benefit that better baseline care has already claimed.

Subject of Research: A cluster-randomised trial of mHealth-based integrated care and comprehensive geriatric assessment in older multimorbid patients with atrial fibrillation.

Article Title: Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial

Article References: Lip, G. Y., Proietti, M., Ainsworth, J., Dan, G.-A., Frost, L., Graffigna, G., Lane, D. A., Lucci, D., Fabbri, G., Marin, F., O'Flaherty, M., Petrovic, M., Potpara, T. S., Proietti, R., Sanaullah, A., Tokmakova, M., Vetrano, D. L., Johnsen, S. P., Maggioni, A. P., … Tokmakova, M. (2026). Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial. The Lancet Regional Health – Europe, 70, Article 101832. https://doi.org/10.1016/j.lanepe.2026.101832

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101832

Keywords: atrial fibrillation, AFFIRMO trial, mHealth, integrated care, ABC pathway, comprehensive geriatric assessment, multimorbidity, cluster-randomised trial, unplanned hospitalisation, digital health, older adults, guideline adherence

The integration of amiodarone into cardiac care has been widely accepted, given its ability to control atrial fibrillation and various ventricular tachyarrhythmias. However, its complex pharmacological profile complicates the dosing and administration. One of the central challenges in treating patients requiring CRRT is ensuring optimal drug levels. Too little can lead to ineffective treatment, while too much can be toxic. This research focuses on determining how CRRT impacts amiodarone levels in the bloodstream, and whether the existing protocols are adequate in maintaining therapeutic ranges.

In the conducted ex vivo study, the team simulated CRRT conditions to investigate amiodarone removal from a biological matrix. Through a sequence of meticulously controlled experiments, they aimed to quantify the extent to which amiodarone could be extracted from the system over varying durations and flow rates commonly employed in clinical practice. The results indicated that while substantial amounts of amiodarone can be removed during CRRT, the effectiveness largely depends on several factors, including blood flow rates and the efficiency of the filtration system used.

The results are timely, considering the increasing prevalence of acute kidney injuries among the severely ill, who may present with complex medication regimens. The data from this research could prompt healthcare providers to rethink their approach to managing drug therapies in patients undergoing CRRT. With cardiovascular stability being a critical aspect of care, understanding the interplay between renal replacement therapies and drug pharmacodynamics has never been more crucial.

Furthermore, the study’s implications extend beyond just amiodarone. The methodologies applied may also be relevant for evaluating other medications commonly administered during CRRT, allowing for a comprehensive understanding of drug removal processes. This could lead to the development of evidence-based guidelines that aid in optimizing medication management for critically ill patients, potentially improving overall outcomes.

One significant takeaway from this research is the highlighted need for continuous monitoring of drug levels in patients undergoing CRRT. Just as one must adjust insulin therapy based on blood glucose levels, similar principles may apply to other medications where extraction rates can significantly alter therapeutic effectiveness. This revelation may catalyze further research into the pharmacokinetics of various drugs in conjunction with CRRT protocols.

Another key aspect of the study was its focus on individual variability. Depending on patient characteristics such as age, weight, renal function, and comorbid conditions, the extraction rates of amiodarone may vary widely among patients. The research underscores the importance of personalized medicine, advocating for tailored approaches to therapy that account for each patient’s unique physiological profile.

Moving forward, the integration of real-time drug monitoring technologies may be beneficial in clinical settings. Devices capable of measuring drug concentrations as they fluctuate could empower healthcare providers to make immediate adjustments to dosing regimens. This would simultaneously enhance patient safety and therapeutic efficacy, closing the gap between clinical practice and pharmacological science.

The excitement surrounding these findings is palpable, as they not only contribute to the body of knowledge regarding amiodarone and CRRT but also inspire broader discussions around renal therapy and medication management. Future studies should aim to replicate these findings in live patients to determine the implications of these results outside of ex vivo simulations.

Moreover, continued innovation in biocompatible materials and CRRT technologies could yield even further enhancements in drug removal efficiencies. With the healthcare landscape continually evolving, it is crucial that advancements in technology keep pace with our understanding of pharmacokinetics in critically ill patients.

As the research lays the groundwork for further inquiry, it is essential for healthcare professionals to stay abreast of developments in the field. Understanding these dynamics will be key in creating treatment regimens that are both effective and safe for patients facing the complexities of acute kidney injury and requiring renal replacement therapy.

In summary, this ex vivo study serves as a catalyst for future investigative pursuits, igniting interest in the intersection between drug therapy and renal support mechanisms. By fostering a collaborative environment among clinicians, researchers, and technologists, the goal of optimized patient care becomes increasingly attainable. With the stakes high in managing patients with intricate health concerns, the commitment to deepening our understanding of foundational pharmacological principles remains a vital pursuit.

This newfound knowledge about the extraction of amiodarone could also fuel discussions about broader implications for drug safety and efficacy in severely ill populations. In the quest for enhanced patient outcomes, this research reiterates the necessity of integrating laboratory findings with real-world clinical practices.

Subject of Research: Amiodarone extraction during continuous renal replacement therapy.

Article Title: Amiodarone extraction by continuous renal replacement therapy: results from an ex vivo study.

Article References:

Green, D.J., McKnite, A.M., Hunt, J.P. et al. Amiodarone extraction by continuous renal replacement therapy: results from an ex vivo study. J Artif Organs 28, 275–279 (2025). https://doi.org/10.1007/s10047-024-01475-7

Image Credits: AI Generated

DOI: 10.1007/s10047-024-01475-7

Keywords: Amiodarone, Continuous Renal Replacement Therapy, Pharmacokinetics, Acute Kidney Injury, Critical Care.

Atrial fibrillation manifests when the atria, the heart’s upper chambers, fail to coordinate effectively with the lower chambers, leading to chaotic electrical activity. This disorder can initially present as occasional irregularities, but if left unchecked, it frequently escalates to a permanent state that introduces various cardiovascular risks. The dynamic nature of AF makes it a particularly complicated condition to study in human subjects, as researchers strive to capture intricate details of the heart’s electrical signaling and cellular behaviors.

Recent research by Moise and his team dives into the heart’s electrical intricacies using sophisticated cardiac electrophysiology models. These models permit the examination of how transient electrical activities—lasting milliseconds to seconds—can bring about substantial long-term changes in cardiac tissue over days, weeks, and even months. This innovative approach aims to encapsulate the nuanced interplay between acute electrical events and chronic cardiac adaptations that contribute to AF’s development.

The simulations undertaken in Moise’s research are groundbreaking, achieving the longest computer simulations of electrical activity in heart tissue to date. By utilizing high-performance computing resources from NCSA and OSC, the research team has managed to simulate up to 24 continuous hours of two-dimensional electrical activity. Such simulations drastically enhance researchers’ ability to manipulate and observe the heart under controlled conditions, a significant advancement given the limitations associated with traditional human studies.

In particular, the simulations harness CUDA code to leverage the power of NVIDIA GPUs, resulting in a remarkable acceleration of computation times. According to Moise, the use of these graphical processing units has enabled the team to expedite their simulations by as much as 250 times compared to running similar workloads on standard personal computers. This efficiency is especially critical as some simulations can last an entire week, which would otherwise equate to years of computation.

The findings from this extensive research dive into the intricacies of calcium homeostasis in heart cells, revealing how adaptations during episodes of rapid heartbeat inadvertently foster an environment conducive to arrhythmias. The heart cells’ ability to balance calcium levels is a remarkable feature, yet it also creates a feedback loop where continual adaptations render the heart increasingly vulnerable to further irregularities. This cycle can lead to a progressive deterioration in heart rhythm, underscoring the importance of early detection and intervention in managing atrial fibrillation.

Moise emphasizes the critical nature of this research in the broader context of health. AF is not merely a benign arrhythmia; it is a leading contributor to morbidity and mortality linked to strokes. By advancing in the understanding of AF through high-fidelity simulations, the goal is to develop better therapeutic interventions that could halt its progression and ultimately mitigate related health risks. The depth of insight gleaned from these studies advocates for proactive measures against AF, establishing a compelling case for heightened awareness and timely treatment.

Future directions for Moise’s research are equally ambitious. The team plans to not only replicate their findings but also explore potential treatment modalities within the simulation environment. By integrating various therapeutic strategies into the computational framework, they hope to validate the impact of these interventions on AF progression. This could have far-reaching implications in clinical settings, providing new avenues for treatment that are grounded in robust, data-driven insights.

The technicality of the research also sheds light on broader implications in the field of biomedical engineering and cardiac health. The methodologies developed in this work are expected to serve as a foundation for studying other cardiac conditions, such as sinoatrial node dysfunction or arrhythmias following myocardial infarctions. Moise’s ambition transcends atrial fibrillation, envisioning a landscape where detailed simulations can address a spectrum of cardiovascular diseases over extended timeframes.

As the research community continues to unravel the complexities of cardiac health, Moise’s work represents a significant milestone in the quest to understand the underlying mechanisms of atrial fibrillation. The implications of such research extend beyond theoretical frameworks, offering tangible pathways to enhance patient care. The advancements made in this study not only pave the way for targeted drug development but also reaffirm the potential of high-performance computing in modern biomedical research.

In conclusion, the innovative approach taken by Moise and his team contributes significantly to the knowledge base surrounding atrial fibrillation. As researchers gain new perspectives on the mechanisms by which AF evolves, the hope is that such insights will translate into more effective treatments. The journey toward better understanding and management of atrial fibrillation continues, driven by technology and a commitment to improving patient outcomes.

Subject of Research: Atrial Fibrillation and its Long-Term Progression
Article Title: Calcium Homeostatic Feedback Control Predicts Atrial Fibrillation Initiation, Remodeling, and Progression
News Publication Date: 15-Jul-2025
Web References: JACC: Clinical Electrophysiology
References: NIH Article on AF
Image Credits: Not provided

Keywords

Atrial Fibrillation, Cardiac Electrophysiology, Calcium Homeostasis, Biomedical Engineering, Supercomputing, Healthcare Research, Cardiovascular Disease, Ischemic Stroke, Nursing Care, Digital Health, Simulation Models, Advanced Computing Technologies.